IP Library › Granted Patent US 12,441,796
Granted Patent B2
US 12,441,796 · App. 17/933,277 · Granted Oct 14, 2025

Antibody constructs for CDH19 and CD3

Inventors: Shouhua Xiao (Foster City, CA); Zheng Pan (Fremont, CA); Dineli Wickramasinghe (San Francisco, CA); M. Shawn Jeffries (Indianapolis, IN); Chadwick Terence King (North Vancouver, CA); Brian Mingtung Chan (Port Coquitlam, CA); Peter Kufer (Munich, DE); Ralf Lutterbüse (Munich, DE); Tobias Raum (Munich, DE); Patrick Hoffmann (Munich, DE); Doris Rau (Munich, DE); Roman Kischel (Munich, DE); Bryan Lemon (Mountain View, CA); Holger Wesche (San Francisco, CA)
Assignees: AMGEN INC.; AMGEN RESEARCH (MUNICH) GMBH
C07K16/2809A61K47/60C07K16/28C07K16/2896C07K16/3053C07K16/468A61K2039/505C07K2317/21C07K2317/31C07K2317/33C07K2317/565C07K2317/569C07K2317/622C07K2317/626C07K2317/73C07K2317/77C07K2317/92C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,441,796
App. No.
17/933,277
Granted
Oct 14, 2025
Kind
B2
Abstract

Provided are antibody constructs comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Also provided are nucleic acids encoding the antibody constructs, vectors comprising the nucleic acids, and host cells transformed or transfected with the vectors. Further provided are a process for the production of the antibody constructs, methods of using the antibody constructs and a kit comprising the antibody constructs.

Claims (80)

1. An antibody construct or an oligomer thereof comprising a first binding domain which binds to human cadherin-19 (CDH19) on the surface of a target cell and a second binding domain which binds to human CD3 epsilon on the surface of a T cell, wherein the first binding domain comprises a VH region comprising CDR-H1, CDR-H2 and CDR-H3 and a VL region comprising CDR-L1, CDR-L2 and CDR-L3 selected from the group consisting of:

(a) CDR-H1 as set forth in SEQ ID NO: 4, CDR-H2 as set forth in SEQ ID NO: 5, CDR-H3 as set forth in SEQ ID NO: 6, CDR-L1 as set forth in SEQ ID NO: 172, CDR-L2 as set forth in SEQ ID NO: 173 and CDR-L3 as set forth in SEQ ID NO: 174;

(b) CDR-H1 as set forth in SEQ ID NO: 10, CDR-H2 as set forth in SEQ ID NO: 11, CDR-H3 as set forth in SEQ ID NO: 12, CDR-L1 as set forth in SEQ ID NO: 178, CDR-L2 as set forth in SEQ ID NO: 179 and CDR-L3 as set forth in SEQ ID NO: 180;

(c) CDR-H1 as set forth in SEQ ID NO: 28, CDR-H2 as set forth in SEQ ID NO: 29, CDR-H3 as set forth in SEQ ID NO: 30, CDR-L1 as set forth in SEQ ID NO: 196, CDR-L2 as set forth in SEQ ID NO: 197 and CDR-L3 as set forth in SEQ ID NO: 198;

(d) CDR-H1 as set forth in SEQ ID NO: 34, CDR-H2 as set forth in SEQ ID NO: 35, CDR-H3 as set forth in SEQ ID NO: 36, CDR-L1 as set forth in SEQ ID NO: 202, CDR-L2 as set forth in SEQ ID NO: 203 and CDR-L3 as set forth in SEQ ID NO: 204;

(e) CDR-H1 as set forth in SEQ ID NO: 46, CDR-H2 as set forth in SEQ ID NO: 47, CDR-H3 as set forth in SEQ ID NO: 48, CDR-L1 as set forth in SEQ ID NO: 214, CDR-L2 as set forth in SEQ ID NO: 215 and CDR-L3 as set forth in SEQ ID NO: 216;

(f) CDR-H1 as set forth in SEQ ID NO: 58, CDR-H2 as set forth in SEQ ID NO: 59, CDR-H3 as set forth in SEQ ID NO: 60, CDR-L1 as set forth in SEQ ID NO: 226, CDR-L2 as set forth in SEQ ID NO: 227 and CDR-L3 as set forth in SEQ ID NO: 228;

(g) CDR-H1 as set forth in SEQ ID NO: 64, CDR-H2 as set forth in SEQ ID NO: 65, CDR-H3 as set forth in SEQ ID NO: 66, CDR-L1 as set forth in SEQ ID NO: 232, CDR-L2 as set forth in SEQ ID NO: 233 and CDR-L3 as set forth in SEQ ID NO: 234;

(h) CDR-H1 as set forth in SEQ ID NO: 70, CDR-H2 as set forth in SEQ ID NO: 71, CDR-H3 as set forth in SEQ ID NO: 72, CDR-L1 as set forth in SEQ ID NO: 238, CDR-L2 as set forth in SEQ ID NO: 239 and CDR-L3 as set forth in SEQ ID NO: 240;

(i) CDR-H1 as set forth in SEQ ID NO: 160, CDR-H2 as set forth in SEQ ID NO: 161, CDR-H3 as set forth in SEQ ID NO: 162, CDR-L1 as set forth in SEQ ID NO: 328, CDR-L2 as set forth in SEQ ID NO: 329 and CDR-L3 as set forth in SEQ ID NO: 330;

(j) CDR-H1 as set forth in SEQ ID NO: 46, CDR-H2 as set forth in SEQ ID NO: 47, CDR-H3 as set forth in SEQ ID NO: 48, CDR-L1 as set forth in SEQ ID NO: 924, CDR-L2 as set forth in SEQ ID NO: 215 and CDR-L3 as set forth in SEQ ID NO: 216;

(k) CDR-H1 as set forth in SEQ ID NO: 46, CDR-H2 as set forth in SEQ ID NO: 47, CDR-H3 as set forth in SEQ ID NO: 902, CDR-L1 as set forth in SEQ ID NO: 924, CDR-L2 as set forth in SEQ ID NO: 215 and CDR-L3 as set forth in SEQ ID NO: 216;

(l) CDR-H1 as set forth in SEQ ID NO: 46, CDR-H2 as set forth in SEQ ID NO: 47, CDR-H3 as set forth in SEQ ID NO: 903, CDR-L1 as set forth in SEQ ID NO: 924, CDR-L2 as set forth in SEQ ID NO: 215 and CDR-L3 as set forth in SEQ ID NO: 216;

(m) CDR-H1 as set forth in SEQ ID NO: 46, CDR-H2 as set forth in SEQ ID NO: 47, CDR-H3 as set forth in SEQ ID NO: 48, CDR-L1 as set forth in SEQ ID NO: 925, CDR-L2 as set forth in SEQ ID NO: 215 and CDR-L3 as set forth in SEQ ID NO: 216;

(n) CDR-H1 as set forth in SEQ ID NO: 70, CDR-H2 as set forth in SEQ ID NO: 907, CDR-H3 as set forth in SEQ ID NO: 72, CDR-L1 as set forth in SEQ ID NO: 238, CDR-L2 as set forth in SEQ ID NO: 239 and CDR-L3 as set forth in SEQ ID NO: 240;

(o) CDR-H1 as set forth in SEQ ID NO: 70, CDR-H2 as set forth in SEQ ID NO: 907, CDR-H3 as set forth in SEQ ID NO: 908, CDR-L1 as set forth in SEQ ID NO: 238, CDR-L2 as set forth in SEQ ID NO: 239 and CDR-L3 as set forth in SEQ ID NO: 240;

(p) CDR-H1 as set forth in SEQ ID NO: 28, CDR-H2 as set forth in SEQ ID NO: 901, CDR-H3 as set forth in SEQ ID NO: 30, CDR-L1 as set forth in SEQ ID NO: 922, CDR-L2 as set forth in SEQ ID NO: 197 and CDR-L3 as set forth in SEQ ID NO: 923;

(q) CDR-H1 as set forth in SEQ ID NO: 58, CDR-H2 as set forth in SEQ ID NO: 905, CDR-H3 as set forth in SEQ ID NO: 906, CDR-L1 as set forth in SEQ ID NO: 226, CDR-L2 as set forth in SEQ ID NO: 227 and CDR-L3 as set forth in SEQ ID NO: 228;

(r) CDR-H1 as set forth in SEQ ID NO: 58, CDR-H2 as set forth in SEQ ID NO: 905, CDR-H3 as set forth in SEQ ID NO: 60, CDR-L1 as set forth in SEQ ID NO: 226, CDR-L2 as set forth in SEQ ID NO: 227 and CDR-L3 as set forth in SEQ ID NO: 228;

(s) CDR-H1 as set forth in SEQ ID NO: 160, CDR-H2 as set forth in SEQ ID NO: 161, CDR-H3 as set forth in SEQ ID NO: 162, CDR-L1 as set forth in SEQ ID NO: 939, CDR-L2 as set forth in SEQ ID NO: 329 and CDR-L3 as set forth in SEQ ID NO: 330;

(t) CDR-H1 as set forth in SEQ ID NO: 160, CDR-H2 as set forth in SEQ ID NO: 921, CDR-H3 as set forth in SEQ ID NO: 162, CDR-L1 as set forth in SEQ ID NO: 939, CDR-L2 as set forth in SEQ ID NO: 329 and CDR-L3 as set forth in SEQ ID NO: 940;

(u) CDR-H1 as set forth in SEQ ID NO: 160, CDR-H2 as set forth in SEQ ID NO: 161, CDR-H3 as set forth in SEQ ID NO: 162, CDR-L1 as set forth in SEQ ID NO: 941, CDR-L2 as set forth in SEQ ID NO: 329 and CDR-L3 as set forth in SEQ ID NO: 330;

(v) CDR-H1 as set forth in SEQ ID NO: 28, CDR-H2 as set forth in SEQ ID NO: 29, CDR-H3 as set forth in SEQ ID NO: 30, CDR-L1 as set forth in SEQ ID NO: 196, CDR-L2 as set forth in SEQ ID NO: 197 and CDR-L3 as set forth in SEQ ID NO: 923;

(w) CDR-H1 as set forth in SEQ ID NO: 28, CDR-H2 as set forth in SEQ ID NO: 29, CDR-H3 as set forth in SEQ ID NO: 30, CDR-L1 as set forth in SEQ ID NO: 922, CDR-L2 as set forth in SEQ ID NO: 197 and CDR-L3 as set forth in SEQ ID NO: 923;

(x) CDR-H1 as set forth in SEQ ID NO: 28, CDR-H2 as set forth in SEQ ID NO: 901, CDR-H3 as set forth in SEQ ID NO: 30, CDR-L1 as set forth in SEQ ID NO: 922, CDR-L2 as set forth in SEQ ID NO: 197 and CDR-L3 as set forth in SEQ ID NO: 923;

(y) CDR-H1 as set forth in SEQ ID NO: 28, CDR-H2 as set forth in SEQ ID NO: 29, CDR-H3 as set forth in SEQ ID NO: 30, CDR-L1 as set forth in SEQ ID NO: 939, CDR-L2 as set forth in SEQ ID NO: 329 and CDR-L3 as set forth in SEQ ID NO: 330;

(z) CDR-H1 as set forth in SEQ ID NO: 970, CDR-H2 as set forth in SEQ ID NO: 971, CDR-H3 as set forth in SEQ ID NO: 972, CDR-L1 as set forth in SEQ ID NO: 973, CDR-L2 as set forth in SEQ ID NO: 974 and CDR-L3 as set forth in SEQ ID NO: 975;

(aa) CDR-H1 as set forth in SEQ ID NO: 1061, CDR-H2 as set forth in SEQ ID NO: 1062, CDR-H3 as set forth in SEQ ID NO: 1063, CDR-L1 as set forth in SEQ ID NO: 1064, CDR-L2 as set forth in SEQ ID NO: 1065 and CDR-L3 as set forth in SEQ ID NO: 1066;

(ab) CDR-H1 as set forth in SEQ ID NO: 1139, CDR-H2 as set forth in SEQ ID NO: 1140, CDR-H3 as set forth in SEQ ID NO: 1141, CDR-L1 as set forth in SEQ ID NO: 1142, CDR-L2 as set forth in SEQ ID NO: 1143 and CDR-L3 as set forth in SEQ ID NO: 1144;

(ac) CDR-H1 as set forth in SEQ ID NO: 1152, CDR-H2 as set forth in SEQ ID NO: 1153, CDR-H3 as set forth in SEQ ID NO: 1154, CDR-L1 as set forth in SEQ ID NO: 1155, CDR-L2 as set forth in SEQ ID NO: 1156 and CDR-L3 as set forth in SEQ ID NO: 1157;

(ad) CDR-H1 as set forth in SEQ ID NO: 1178, CDR-H2 as set forth in SEQ ID NO: 1179, CDR-H3 as set forth in SEQ ID NO: 1180, CDR-L1 as set forth in SEQ ID NO: 1181, CDR-L2 as set forth in SEQ ID NO: 1182 and CDR-L3 as set forth in SEQ ID NO: 1183;

(ae) CDR-H1 as set forth in SEQ ID NO: 1191, CDR-H2 as set forth in SEQ ID NO: 1192, CDR-H3 as set forth in SEQ ID NO: 1193, CDR-L1 as set forth in SEQ ID NO: 1194, CDR-L2 as set forth in SEQ ID NO: 1195 and CDR-L3 as set forth in SEQ ID NO: 1196;

(af) CDR-H1 as set forth in SEQ ID NO: 1204, CDR-H2 as set forth in SEQ ID NO: 1205, CDR-H3 as set forth in SEQ ID NO: 1206, CDR-L1 as set forth in SEQ ID NO: 1207, CDR-L2 as set forth in SEQ ID NO: 1208 and CDR-L3 as set forth in SEQ ID NO: 1209;

(ag) CDR-H1 as set forth in SEQ ID NO: 1217, CDR-H2 as set forth in SEQ ID NO: 1218, CDR-H3 as set forth in SEQ ID NO: 1219, CDR-L1 as set forth in SEQ ID NO: 1220, CDR-L2 as set forth in SEQ ID NO: 1221 and CDR-L3 as set forth in SEQ ID NO: 1222;

(ah) CDR-H1 as set forth in SEQ ID NO: 1230, CDR-H2 as set forth in SEQ ID NO: 1231, CDR-H3 as set forth in SEQ ID NO: 1232, CDR-L1 as set forth in SEQ ID NO: 1233, CDR-L2 as set forth in SEQ ID NO: 1234 and CDR-L3 as set forth in SEQ ID NO: 1235;

(ai) CDR-H1 as set forth in SEQ ID NO: 1308, CDR-H2 as set forth in SEQ ID NO: 1309, CDR-H3 as set forth in SEQ ID NO: 1310, CDR-L1 as set forth in SEQ ID NO: 1311, CDR-L2 as set forth in SEQ ID NO: 1312 and CDR-L3 as set forth in SEQ ID NO: 1313;

(aj) CDR-H1 as set forth in SEQ ID NO: 1321, CDR-H2 as set forth in SEQ ID NO: 1322, CDR-H3 as set forth in SEQ ID NO: 1323, CDR-L1 as set forth in SEQ ID NO: 1324, CDR-L2 as set forth in SEQ ID NO: 1325 and CDR-L3 as set forth in SEQ ID NO: 1326;

(ak) CDR-H1 as set forth in SEQ ID NO: 1373, CDR-H2 as set forth in SEQ ID NO: 1374, CDR-H3 as set forth in SEQ ID NO: 1375, CDR-L1 as set forth in SEQ ID NO: 1376, CDR-L2 as set forth in SEQ ID NO: 1377 and CDR-L3 as set forth in SEQ ID NO: 1378;

(al) CDR-H1 as set forth in SEQ ID NO: 1386, CDR-H2 as set forth in SEQ ID NO: 1387, CDR-H3 as set forth in SEQ ID NO: 1388, CDR-L1 as set forth in SEQ ID NO: 1389, CDR-L2 as set forth in SEQ ID NO: 1390 and CDR-L3 as set forth in SEQ ID NO: 1391;

(am) CDR-H1 as set forth in SEQ ID NO: 1399, CDR-H2 as set forth in SEQ ID NO: 1400, CDR-H3 as set forth in SEQ ID NO: 1401, CDR-L1 as set forth in SEQ ID NO: 1402, CDR-L2 as set forth in SEQ ID NO: 1403 and CDR-L3 as set forth in SEQ ID NO: 1404;

(an) CDR-H1 as set forth in SEQ ID NO: 1412, CDR-H2 as set forth in SEQ ID NO: 1413, CDR-H3 as set forth in SEQ ID NO: 1414, CDR-L1 as set forth in SEQ ID NO: 1415, CDR-L2 as set forth in SEQ ID NO: 1416 and CDR-L3 as set forth in SEQ ID NO: 1417;

(ao) CDR-H1 as set forth in SEQ ID NO: 1777, CDR-H2 as set forth in SEQ ID NO: 1778, CDR-H3 as set forth in SEQ ID NO: 1779, CDR-L1 as set forth in SEQ ID NO: 1780, CDR-L2 as set forth in SEQ ID NO: 1781 and CDR-L3 as set forth in SEQ ID NO: 1782;

(ap) CDR-H1 as set forth in SEQ ID NO: 1790, CDR-H2 as set forth in SEQ ID NO: 1791, CDR-H3 as set forth in SEQ ID NO: 1792, CDR-L1 as set forth in SEQ ID NO: 1793, CDR-L2 as set forth in SEQ ID NO: 1794 and CDR-L3 as set forth in SEQ ID NO: 1795;

(aq) CDR-H1 as set forth in SEQ ID NO: 1803, CDR-H2 as set forth in SEQ ID NO: 1804, CDR-H3 as set forth in SEQ ID NO: 1805, CDR-L1 as set forth in SEQ ID NO: 1806, CDR-L2 as set forth in SEQ ID NO: 1807 and CDR-L3 as set forth in SEQ ID NO: 1808;

(ar) CDR-H1 as set forth in SEQ ID NO: 1816, CDR-H2 as set forth in SEQ ID NO: 1817, CDR-H3 as set forth in SEQ ID NO: 1818, CDR-L1 as set forth in SEQ ID NO: 1819, CDR-L2 as set forth in SEQ ID NO: 1820 and CDR-L3 as set forth in SEQ ID NO: 1821;

(as) CDR-H1 as set forth in SEQ ID NO: 1829, CDR-H2 as set forth in SEQ ID NO: 1830, CDR-H3 as set forth in SEQ ID NO: 1831, CDR-L1 as set forth in SEQ ID NO: 1832, CDR-L2 as set forth in SEQ ID NO: 1833 and CDR-L3 as set forth in SEQ ID NO: 1834;

(at) CDR-H1 as set forth in SEQ ID NO: 1842, CDR-H2 as set forth in SEQ ID NO: 1843, CDR-H3 as set forth in SEQ ID NO: 1844, CDR-L1 as set forth in SEQ ID NO: 1845, CDR-L2 as set forth in SEQ ID NO: 1846 and CDR-L3 as set forth in SEQ ID NO: 1847;

(au) CDR-H1 as set forth in SEQ ID NO: 1855, CDR-H2 as set forth in SEQ ID NO: 1856, CDR-H3 as set forth in SEQ ID NO: 1857, CDR-L1 as set forth in SEQ ID NO: 1858, CDR-L2 as set forth in SEQ ID NO: 1859 and CDR-L3 as set forth in SEQ ID NO: 1860;

(av) CDR-H1 as set forth in SEQ ID NO: 1868, CDR-H2 as set forth in SEQ ID NO: 1869, CDR-H3 as set forth in SEQ ID NO: 1870, CDR-L1 as set forth in SEQ ID NO: 1871, CDR-L2 as set forth in SEQ ID NO: 1872 and CDR-L3 as set forth in SEQ ID NO: 1873;

(aw) CDR-H1 as set forth in SEQ ID NO: 1881, CDR-H2 as set forth in SEQ ID NO: 1882, CDR-H3 as set forth in SEQ ID NO: 1883, CDR-L1 as set forth in SEQ ID NO: 1884, CDR-L2 as set forth in SEQ ID NO: 1885 and CDR-L3 as set forth in SEQ ID NO: 1886;

(ax) CDR-H1 as set forth in SEQ ID NO: 2063, CDR-H2 as set forth in SEQ ID NO: 2064, CDR-H3 as set forth in SEQ ID NO: 2065, CDR-L1 as set forth in SEQ ID NO: 2066, CDR-L2 as set forth in SEQ ID NO: 2067 and CDR-L3 as set forth in SEQ ID NO: 2068;

(ay) CDR-H1 as set forth in SEQ ID NO: 2076, CDR-H2 as set forth in SEQ ID NO: 2077, CDR-H3 as set forth in SEQ ID NO: 2078, CDR-L1 as set forth in SEQ ID NO: 2079, CDR-L2 as set forth in SEQ ID NO: 2080 and CDR-L3 as set forth in SEQ ID NO: 2081;

(az) CDR-H1 as set forth in SEQ ID NO: 2089, CDR-H2 as set forth in SEQ ID NO: 2090, CDR-H3 as set forth in SEQ ID NO: 2091, CDR-L1 as set forth in SEQ ID NO: 2092, CDR-L2 as set forth in SEQ ID NO: 2093 and CDR-L3 as set forth in SEQ ID NO: 2094;

(aaa) CDR-H1 as set forth in SEQ ID NO: 2102, CDR-H2 as set forth in SEQ ID NO: 2103, CDR-H3 as set forth in SEQ ID NO: 2104, CDR-L1 as set forth in SEQ ID NO: 2105, CDR-L2 as set forth in SEQ ID NO: 2106 and CDR-L3 as set forth in SEQ ID NO: 2107;

(aab) CDR-H1 as set forth in SEQ ID NO: 2115, CDR-H2 as set forth in SEQ ID NO: 2116, CDR-H3 as set forth in SEQ ID NO: 2117, CDR-L1 as set forth in SEQ ID NO: 2118, CDR-L2 as set forth in SEQ ID NO: 2119 and CDR-L3 as set forth in SEQ ID NO: 2120;

(aac) CDR-H1 as set forth in SEQ ID NO: 2128, CDR-H2 as set forth in SEQ ID NO: 2129, CDR-H3 as set forth in SEQ ID NO: 2130, CDR-L1 as set forth in SEQ ID NO: 2131, CDR-L2 as set forth in SEQ ID NO: 2132 and CDR-L3 as set forth in SEQ ID NO: 2133;

(aad) CDR-H1 as set forth in SEQ ID NO: 2141, CDR-H2 as set forth in SEQ ID NO: 2142, CDR-H3 as set forth in SEQ ID NO: 2143, CDR-L1 as set forth in SEQ ID NO: 2144, CDR-L2 as set forth in SEQ ID NO: 2145 and CDR-L3 as set forth in SEQ ID NO: 2146;

(aae) CDR-H1 as set forth in SEQ ID NO: 2154, CDR-H2 as set forth in SEQ ID NO: 2155, CDR-H3 as set forth in SEQ ID NO: 2156, CDR-L1 as set forth in SEQ ID NO: 2157, CDR-L2 as set forth in SEQ ID NO: 2158 and CDR-L3 as set forth in SEQ ID NO: 2159;

(aaf) CDR-H1 as set forth in SEQ ID NO: 2180, CDR-H2 as set forth in SEQ ID NO: 2181, CDR-H3 as set forth in SEQ ID NO: 2182, CDR-L1 as set forth in SEQ ID NO: 2183, CDR-L2 as set forth in SEQ ID NO: 2184 and CDR-L3 as set forth in SEQ ID NO: 2185;

(aag) CDR-H1 as set forth in SEQ ID NO: 2193, CDR-H2 as set forth in SEQ ID NO: 2194, CDR-H3 as set forth in SEQ ID NO: 2195, CDR-L1 as set forth in SEQ ID NO: 2196, CDR-L2 as set forth in SEQ ID NO: 2197 and CDR-L3 as set forth in SEQ ID NO: 2198; and

(aah) CDR-H1 as set forth in SEQ ID NO: 2206, CDR-H2 as set forth in SEQ ID NO: 2207, CDR-H3 as set forth in SEQ ID NO: 2208, CDR-L1 as set forth in SEQ ID NO: 2209, CDR-L2 as set forth in SEQ ID NO: 2210 and CDR-L3 as set forth in SEQ ID NO: 2211.

2. The antibody construct or the oligomer thereof of claim 1 , wherein the first binding domain comprises a VH region comprising the amino acid sequence set forth in SEQ ID NO: 352, SEQ ID NO: 360, SEQ ID NO: 388, SEQ ID NO: 386, SEQ ID NO: 340, SEQ ID NO: 346, SEQ ID NO: 374, SEQ ID NO: 348, SEQ ID NO: 390, SEQ ID NO: 463, SEQ ID NO: 464, SEQ ID NO: 465, SEQ ID NO: 466, SEQ ID NO: 467, SEQ ID NO: 468, SEQ ID NO: 469, SEQ ID NO: 470, SEQ ID NO: 471, SEQ ID NO: 472, SEQ ID NO: 473, SEQ ID NO: 474, SEQ ID NO: 475, SEQ ID NO: 488, SEQ ID NO: 489, SEQ ID NO: 490, SEQ ID NO: 491, SEQ ID NO: 513, SEQ ID NO: 514, SEQ ID NO: 515, SEQ ID NO: 516, SEQ ID NO: 540, SEQ ID NO: 541, SEQ ID NO: 542, SEQ ID NO: 543, SEQ ID NO: 977, SEQ ID NO: 1068, SEQ ID NO: 1146, SEQ ID NO: 1159, SEQ ID NO: 1185, SEQ ID NO: 1198, SEQ ID NO: 1211, SEQ ID NO: 1224, SEQ ID NO: 1237, SEQ ID NO: 1315, SEQ ID NO: 1328, SEQ ID NO: 1380, SEQ ID NO: 1393, SEQ ID NO: 1406, SEQ ID NO: 1419, SEQ ID NO: 1469, SEQ ID NO: 1478, SEQ ID NO: 1485, SEQ ID NO: 1494, SEQ ID NO: 1501, SEQ ID NO: 1508, SEQ ID NO: 1519, SEQ ID NO: 1526, SEQ ID NO: 1533, SEQ ID NO: 1542, SEQ ID NO: 1549, SEQ ID NO: 1558, SEQ ID NO: 1565, SEQ ID NO: 1784, SEQ ID NO: 1797, SEQ ID NO: 1810, SEQ ID NO: 1823, SEQ ID NO: 1836, SEQ ID NO: 1849, SEQ ID NO: 1862, SEQ ID NO: 1875, SEQ ID NO: 1888, SEQ ID NO: 2070, SEQ ID NO: 2083, SEQ ID NO: 2096, SEQ ID NO: 2109, SEQ ID NO: 2122, SEQ ID NO: 2135, SEQ ID NO: 2148, SEQ ID NO: 2161, SEQ ID NO: 2187, SEQ ID NO: 2200, or SEQ ID NO: 2213.

3. The antibody construct or the oligomer thereof of claim 1 , wherein the first binding domain comprises a VL region comprising the amino acid sequence set forth in SEQ ID NO: 408, SEQ ID NO: 416, SEQ ID NO: 444, SEQ ID NO: 442, SEQ ID NO: 396, SEQ ID NO: 402, SEQ ID NO: 430, SEQ ID NO: 404, SEQ ID NO: 446, SEQ ID NO: 558, SEQ ID NO: 559, SEQ ID NO: 560, SEQ ID NO: 561, SEQ ID NO: 562, SEQ ID NO: 563, SEQ ID NO: 564, SEQ ID NO: 565, SEQ ID NO: 566, SEQ ID NO: 567, SEQ ID NO: 568, SEQ ID NO: 569, SEQ ID NO: 570, SEQ ID NO: 583, SEQ ID NO: 584, SEQ ID NO: 585, SEQ ID NO: 586, SEQ ID NO: 608, SEQ ID NO: 609, SEQ ID NO: 610, SEQ ID NO: 611, SEQ ID NO: 635, SEQ ID NO: 636, SEQ ID NO: 637, SEQ ID NO: 638, SEQ ID NO: 979, SEQ ID NO: 1070, SEQ ID NO: 1148, SEQ ID NO: 1161, SEQ ID NO: 1187, SEQ ID NO: 1200, SEQ ID NO: 1213, SEQ ID NO: 1226, SEQ ID NO: 1239, SEQ ID NO: 1317, SEQ ID NO: 1330, SEQ ID NO: 1382, SEQ ID NO: 1395, SEQ ID NO: 1408, SEQ ID NO: 1421, SEQ ID NO: 1471, SEQ ID NO: 1480, SEQ ID NO: 1487, SEQ ID NO: 1496, SEQ ID NO: 1503, SEQ ID NO: 1510, SEQ ID NO: 1521, SEQ ID NO: 1528, SEQ ID NO: 1535, SEQ ID NO: 1544, SEQ ID NO: 1551, SEQ ID NO: 1560, SEQ ID NO: 1567, SEQ ID NO: 1786, SEQ ID NO: 1799, SEQ ID NO: 1812, SEQ ID NO: 1825, SEQ ID NO: 1838, SEQ ID NO: 1851, SEQ ID NO: 1864, SEQ ID NO: 1877, SEQ ID NO: 1890, SEQ ID NO: 2072, SEQ ID NO: 2085, SEQ ID NO: 2098, SEQ ID NO: 2111, SEQ ID NO: 2124, SEQ ID NO: 2137, SEQ ID NO: 2150, SEQ ID NO: 2163, SEQ ID NO: 2189, SEQ ID NO: 2202, or SEQ ID NO: 2215.

4. The antibody construct or the oligomer thereof of claim 1 , wherein the first binding domain comprises a VH region and a VL region comprising SEQ ID NOs: 352 and 408, SEQ ID NOs: 360 and 416, SEQ ID NOs: 388 and 444, SEQ ID NOs: 386 and 442, SEQ ID NOs: 340 and 396, SEQ ID NOs: 346 and 402, SEQ ID NOs: 374 and 430, SEQ ID NOs: 348 and 404, SEQ ID NOs: 390 and 446, SEQ ID NOs: 463 and 558, SEQ ID NOs: 464 and 559, SEQ ID NOs: 465 and 560, SEQ ID NOs: 466 and 561, SEQ ID NOs: 467 and 562, SEQ ID NOs: 468 and 563, SEQ ID NOs: 469 and 564, SEQ ID NOs: 470 and 565, SEQ ID NOs: 471 and 566, SEQ ID NOs: 472 and 567, SEQ ID NOs: 473 and 568, SEQ ID NOs: 474 and 569, SEQ ID NOs: 475 and 570, SEQ ID NOs: 488 and 583, SEQ ID NOs: 489 and 584, SEQ ID NOs: 490 and 585, SEQ ID NOs: 491 and 586, SEQ ID NOs: 513 and 608, SEQ ID NOs: 514 and 609, SEQ ID NOs: 515 and 610, SEQ ID NOs: 516 and 611, SEQ ID NOs: 540 and 635, SEQ ID NOs: 541 and 636, SEQ ID NOs: 542 and 637, SEQ ID NOs: 543 and 638, SEQ ID NOs: 977 and 979, SEQ ID NOs: 1068 and 1070, SEQ ID NOs: 1146 and 1148, SEQ ID NOs: 1159 and 1161, SEQ ID NOs: 1185 and 1187, SEQ ID NOs: 1198 and 1200, SEQ ID NOs: 1211 and 1213, SEQ ID NOs: 1224 and 1226, SEQ ID NOs: 1237 and 1239, SEQ ID NOs: 1315 and 1317, SEQ ID NOs: 1328 and 1330, SEQ ID NOs: 1380 and 1382 SEQ ID NOs: 1393 and 1395, SEQ ID NOs: 1406 and 1408, SEQ ID NOs: 1419 and 1421, SEQ ID NOs: 1469 and 1471, SEQ ID NOs: 1478 and 1480, SEQ ID NOs: 1485 and 1487, SEQ ID NOs: 1494 and 1496, SEQ ID NOs: 1501 and 1503, SEQ ID NOs: 1508 and 1510, SEQ ID NOs: 1519 and 1521, SEQ ID NOs: 1526 and 1528, SEQ ID NOs: 1533 and 1535, SEQ ID NOs: 1542 and 1544, SEQ ID NOs: 1549 and 1551, SEQ ID NOs: 1558 and 1560, SEQ ID NOs: 1565 and 1567, SEQ ID NOs: 1784 and 1786, SEQ ID NOs: 1797 and 1799, SEQ ID NOs: 1810 and 1812, SEQ ID NOs: 1823 and 1825, SEQ ID NOs: 1836 and 1838, SEQ ID NOs: 1849 and 1851, SEQ ID NOs: 1862 and 1864, SEQ ID NOs: 1875 and 1877, SEQ ID NOs: 1888 and 1890, SEQ ID NOs: 2070 and 2072, SEQ ID NOs: 2083 and 2085, SEQ ID NOs: 2096 and 2098, SEQ ID NOs: 2109 and 2111, SEQ ID NOs: 2122 and 2124, SEQ ID NOs: 2135 and 2137, SEQ ID NOs: 2148 and 2150, SEQ ID NOs: 2161 and 2163, SEQ ID NOs: 2187 and 2189, SEQ ID NOs: 2200 and 2202, or SEQ ID NOs: 2213 and 2215.

5. The antibody construct or the oligomer thereof of claim 1 , wherein the antibody construct or the oligomer thereof is in a format of a single chain bispecific antibody (scFv) 2 or a diabody.

6. The antibody construct or the oligomer thereof of claim 5 , wherein the first binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 981, SEQ ID NO: 1072, SEQ ID NO: 1150, SEQ ID NO: 1163, SEQ ID NO: 1189, SEQ ID NO: 1202, SEQ ID NO: 1215, SEQ ID NO: 1228, SEQ ID NO: 1241, SEQ ID NO: 1319, SEQ ID NO: 1332, SEQ ID NO: 1384, SEQ ID NO: 1397, SEQ ID NO: 1410, SEQ ID NO: 1423, SEQ ID NO: 1473, SEQ ID NO: 1482, SEQ ID NO: 1489, SEQ ID NO: 1498, SEQ ID NO: 1505, SEQ ID NO: 1512, SEQ ID NO: 1523, SEQ ID NO: 1530, SEQ ID NO: 1537, SEQ ID NO: 1546, SEQ ID NO: 1553, SEQ ID NO: 1562, SEQ ID NO: 1569, SEQ ID NO: 1788, SEQ ID NO: 1801, SEQ ID NO: 1814, SEQ ID NO: 1827, SEQ ID NO: 1840, SEQ ID NO: 1853, SEQ ID NO: 1866, SEQ ID NO: 1879, SEQ ID NO: 1892, SEQ ID NO: 2074, SEQ ID NO: 2087, SEQ ID NO: 2100, SEQ ID NO: 2113, SEQ ID NO: 2126, SEQ ID NO: 2139, SEQ ID NO: 2152, SEQ ID NO: 2165, SEQ ID NO: 2191, SEQ ID NO: 2204, and SEQ ID NO: 2217.

7. The antibody construct or the oligomer thereof of claim 1 , wherein the second binding domain further binds to any of Callithrix jacchus, Saguinus oedipus and/or Saimiri sciureus CD3 epsilon.

8. The antibody construct or the oligomer thereof of claim 7 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 982, SEQ ID NO: 1073, SEQ ID NO: 1151, SEQ ID NO: 1164, SEQ ID NO: 1190, SEQ ID NO: 1203, SEQ ID NO: 1216, SEQ ID NO: 1229, SEQ ID NO: 1242, SEQ ID NO: 1320, SEQ ID NO: 1333, SEQ ID NO: 1385, SEQ ID NO: 1398, SEQ ID NO: 1411, SEQ ID NO: 1424, SEQ ID NO: 1474, SEQ ID NO: 1475, SEQ ID NO: 1476, SEQ ID NO: 1483, SEQ ID NO: 1490, SEQ ID NO: 1491, SEQ ID NO: 1492, SEQ ID NO: 1499, SEQ ID NO: 1506, SEQ ID NO: 1513, SEQ ID NO: 1514, SEQ ID NO: 1515, SEQ ID NO: 1516, SEQ ID NO: 1517, SEQ ID NO: 1524, SEQ ID NO: 1531, SEQ ID NO: 1538, SEQ ID NO: 1539, SEQ ID NO: 1540, SEQ ID NO: 1547, SEQ ID NO: 1554, SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1563, SEQ ID NO: 1570, SEQ ID NO: 1571, SEQ ID NO: 1572, SEQ ID NO: 1573, SEQ ID NO: 1574, SEQ ID NO: 1575, SEQ ID NO: 1576, SEQ ID NO: 1577, SEQ ID NO: 1578, SEQ ID NO: 1579, SEQ ID NO: 1580, SEQ ID NO: 1581, SEQ ID NO: 1789, SEQ ID NO: 1802, SEQ ID NO: 1815, SEQ ID NO: 1828, SEQ ID NO: 1841, SEQ ID NO: 1854, SEQ ID NO: 1867, SEQ ID NO: 1880, SEQ ID NO: 1893, SEQ ID NO: 2075, SEQ ID NO: 2088, SEQ ID NO: 2101, SEQ ID NO: 2114, SEQ ID NO: 2127, SEQ ID NO: 2140, SEQ ID NO: 2153, SEQ ID NO: 2166, SEQ ID NO: 2192, SEQ ID NO: 2205, and SEQ ID NO: 2218 to SEQ ID NO: 2228.

9. A nucleic acid comprising a nucleotide sequence encoding the antibody construct or the oligomer thereof of claim 1 .

10. A vector comprising the nucleic acid of claim 9 .

11. A host cell transformed or transfected with the nucleic acid of claim 9 .

12. A process for producing an antibody construct or an oligomer thereof, the process comprising culturing the host cell of claim 11 under conditions allowing the expression of the antibody construct or the oligomer thereof.

13. A composition comprising the antibody construct or the oligomer thereof of claim 1 and a carrier, stabilizer and/or excipient.

14. A method for treating or ameliorating a subject having a melanoma disease expressing human cadherin-19 (CDH19) comprising the step of administering to the subject having the melanoma disease an effective amount of the antibody construct or the oligomer thereof of claim 1 .

15. The method of claim 14 , wherein the melanoma disease is selected from the group consisting of superficial spreading melanoma, lentigo maligna, lentigo maligna melanoma, acral lentiginous melanoma and nodular melanoma.

16. A kit comprising the antibody construct or the oligomer thereof of claim 1 and

(a) a container for storing the antibody construct or the oligomer thereof,

(b) a syringe for delivering the antibody construct or the oligomer thereof, or

(c) a combination of (a) and (b).

17. The method of claim 14 , wherein the melanoma disease is a metastatic melanoma disease.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S STREET ADDRESS PREVIOUSLY RECORDED AT REEL: 062312 FRAME: 0219. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Jan 23, 2023
From: KUFER, PETER; LUTTERBÜESE, RALF; RAUM, TOBIAS; HOFFMANN, PATRICK; RAU, DORIS; KISCHEL, ROMAN
To: AMGEN RESEARCH (MUNICH) GMBH
Reel/Frame 062460/0950 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2023
From: KUFER, PETER; LUTTERBÜESE, RALF; RAUM, TOBIAS; HOFFMANN, PATRICK; RAU, DORIS; KISCHEL, ROMAN
To: AMGEN RESEARCH (MUNICH) GMBH
Reel/Frame 062312/0219 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2023
From: XIAO, SHOUHUA; PAN, ZHENG; WICKRAMASINGHE, DINELI; JEFFRIES, M. SHAWN; LEMON, BRYAN; WESCHE, HOLGER; KING, CHADWICK TERENCE; CHAN, BRIAN MINGTUNG
To: AMGEN INC.
Reel/Frame 062312/0916 →
Continuity (5)
Division 16040927 · Jul 20, 2018
Division 14761839
Provisional Application 61785147 · Mar 14, 2013
Provisional Application 61756991 · Jan 25, 2013
Related Publication 20240010724A1 · Jan 11, 2024
References Cited (244)
US 3691016A · Patel et al. · 1972 [cited by applicant]
US 3773919A · Boswell et al. · 1973 [cited by applicant]
US 3969287A · Jaworek et al. · 1976 [cited by applicant]
US 4179337A · Davis et al. · 1979 [cited by applicant]
US 4195128A · Hildebrand et al. · 1980 [cited by applicant]
US 4229537A · Hodgins et al. · 1980 [cited by applicant]
US 4247642A · Hirohara et al. · 1981 [cited by applicant]
US 4301144A · Iwashita et al. · 1981 [cited by applicant]
US 4330440A · Ayers et al. · 1982 [cited by applicant]
US 4485045A · Regen · 1984 [cited by applicant]
US 4496689A · Mitra · 1985 [cited by applicant]
US 4544545A · Ryan et al. · 1985 [cited by applicant]
US 4640835A · Shimizu et al. · 1987 [cited by applicant]
US 4670417A · Iwasaki et al. · 1987 [cited by applicant]
US 4751180A · Cousens et al. · 1988 [cited by applicant]
US 4791192A · Nakagawa et al. · 1988 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4935233A · Bell et al. · 1990 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 5013556A · Woodle et al. · 1991 [cited by applicant]
US 5292658A · Cormier et al. · 1994 [cited by applicant]
US 5418155A · Cormier et al. · 1995 [cited by applicant]
US 5476996A · Wilson et al. · 1995 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5591669A · Krimpenfort et al. · 1997 [cited by applicant]
US 5612205A · Kay et al. · 1997 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5625825A · Rostoker et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5643763A · Dunn et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5683888A · Campbell · 1997 [cited by applicant]
US 5698767A · Wilson et al. · 1997 [cited by applicant]
US 5721367A · Kay et al. · 1998 [cited by applicant]
US 5741668A · Ward et al. · 1998 [cited by applicant]
US 5770429A · Lonberg et al. · 1998 [cited by applicant]
US 5777079A · Tsien et al. · 1998 [cited by applicant]
US 5789215A · Berns et al. · 1998 [cited by applicant]
US 5789650A · Lonberg et al. · 1998 [cited by applicant]
US 5804387A · Cormack et al. · 1998 [cited by applicant]
US 5814318A · Lonberg et al. · 1998 [cited by applicant]
US 5874299A · Lonberg et al. · 1999 [cited by applicant]
US 5874304A · Zolotukhin et al. · 1999 [cited by applicant]
US 5876995A · Bryan · 1999 [cited by applicant]
US 5877397A · Lonberg et al. · 1999 [cited by applicant]
US 5939598A · Kucherlapati et al. · 1999 [cited by applicant]
US 5958765A · Brams et al. · 1999 [cited by applicant]
US 5981175A · Loring et al. · 1999 [cited by applicant]
US 6023010A · Krimpenfort et al. · 2000 [cited by applicant]
US 6075181A · Kucherlapati et al. · 2000 [cited by applicant]
US 6114598A · Kucherlapati et al. · 2000 [cited by applicant]
US 6150584A · Kucherlapati et al. · 2000 [cited by applicant]
US 6162963A · Kucherlapati et al. · 2000 [cited by applicant]
US 6255458B1 · Lonberg et al. · 2001 [cited by applicant]
US 6673986B1 · Kucherlapati et al. · 2004 [cited by applicant]
US 6833268B1 · Green et al. · 2004 [cited by applicant]
US 7049426B2 · Green et al. · 2006 [cited by applicant]
US 7064244B2 · Jakobovits et al. · 2006 [cited by applicant]
US 9243058B2 · Armitage et al. · 2016 [cited by applicant]
US 9765157B2 · Xiao · 2017 [cited by examiner]
US 9920121B2 · Xiao · 2018 [cited by examiner]
US 10294300B2 · Raum et al. · 2019 [cited by applicant]
US 10301391B2 · Raum et al. · 2019 [cited by applicant]
US 11053311B2 · Xiao · 2021 [cited by examiner]
US 12297292B2 · Xiao · 2025 [cited by examiner]
US 20070161018A1 · Inazawa et al. · 2007 [cited by applicant]
US 20100131432A1 · Kennedy et al. · 2010 [cited by applicant]
US 20140322218A1 · Xiao et al. · 2014 [cited by applicant]
US 20150322151A1 · Xiao et al. · 2015 [cited by applicant]
US 20160115241A1 · Yan et al. · 2016 [cited by applicant]
US 20160326594A1 · Srivastava et al. · 2016 [cited by applicant]
US 20170029502A1 · Raum et al. · 2017 [cited by applicant]
US 20170029512A1 · Raum et al. · 2017 [cited by applicant]
US 20170037149A1 · Raum et al. · 2017 [cited by applicant]
US 20170129961A1 · Raum et al. · 2017 [cited by applicant]
US 20170218078A1 · Raum et al. · 2017 [cited by applicant]
US 20170218079A1 · Raum et al. · 2017 [cited by applicant]
US 20170349668A1 · Rattel et al. · 2017 [cited by applicant]
US 20180002450A1 · Xiao · 2018 [cited by examiner]
US 20200071405A1 · Xiao et al. · 2020 [cited by applicant]
US 20210163592A1 · Goudar et al. · 2021 [cited by applicant]
EP 0036676A1 · 1981 [cited by applicant]
EP 0058481A1 · 1982 [cited by applicant]
EP 0088046A2 · 1983 [cited by applicant]
EP 0133988A2 · 1985 [cited by applicant]
EP 0143949A1 · 1985 [cited by applicant]
EP 0463151A1 · 1992 [cited by applicant]
EP 773288A2 · 1997 [cited by applicant]
EP 843961A1 · 1998 [cited by applicant]
EP 2258874B1 · 2015 [cited by applicant]
JP 3068180B2 · 2000 [cited by applicant]
JP 3068506B2 · 2000 [cited by applicant]
JP 3068507B2 · 2000 [cited by applicant]
JP 2008521411A · 2008 [cited by applicant]
JP 2009504191A · 2009 [cited by applicant]
JP 2010524851A · 2010 [cited by applicant]
TW 1323734B · 2010 [cited by applicant]
WO WO8705330A1 · 1987 [cited by applicant]
WO WO198809344A1 · 1988 [cited by applicant]
WO WO9203918A1 · 1992 [cited by applicant]
WO WO199215673A1 · 1992 [cited by applicant]
WO WO199222647A1 · 1992 [cited by applicant]
WO WO199222670A1 · 1992 [cited by applicant]
WO WO199312227A1 · 1993 [cited by applicant]
WO WO199315722A1 · 1993 [cited by applicant]
WO WO199400569A1 · 1994 [cited by applicant]
WO WO9402602A1 · 1994 [cited by applicant]
WO WO9410308A1 · 1994 [cited by applicant]
WO WO199425585A1 · 1994 [cited by applicant]
WO WO199507463A1 · 1995 [cited by applicant]
WO WO199614436A1 · 1996 [cited by applicant]
WO WO9634096A1 · 1996 [cited by applicant]
WO WO199713852A1 · 1997 [cited by applicant]
WO WO199814605A1 · 1998 [cited by applicant]
WO WO9824893A2 · 1998 [cited by applicant]
WO WO199824884A1 · 1998 [cited by applicant]
WO WO199826277A2 · 1998 [cited by applicant]
WO WO199949019A2 · 1999 [cited by applicant]
WO WO199954440A1 · 1999 [cited by applicant]
WO WO200076310A1 · 2000 [cited by applicant]
WO WO200347336A2 · 2003 [cited by applicant]
WO WO2004003019A2 · 2004 [cited by applicant]
WO WO200567391A2 · 2005 [cited by applicant]
WO WO2006071441A2 · 2006 [cited by applicant]
WO WO2006138181A2 · 2006 [cited by applicant]
WO WO2007024715A2 · 2007 [cited by applicant]
WO WO2007042261A2 · 2007 [cited by applicant]
WO WO2008119567A2 · 2008 [cited by applicant]
WO WO200955937A1 · 2009 [cited by applicant]
WO WO2010037835A2 · 2010 [cited by applicant]
Almagro & Franssen, Frontiers in Bioscience, 13:1619-33 (2008). [cited by examiner]
Edwards et al., J Mol Biol 334:103-118 (2003). [cited by examiner]
Marchalonis et al., Dev & Comp Immunol. 30:223-247 (2006). [cited by examiner]
Lippow et al., Nature Biotechnology, 25(10):1171-1176 (2007). [cited by examiner]
Altshuler et al., Biochemistry (Moscow), 75(13):1584-1605 (2010). [cited by examiner]
Lutterbuese, R. et al., Proc. Natl. Acad. Sci. USA 107, 12605-12610 (2010). [cited by examiner]
Weißmüller et al.(PLoS One. 2016; 11(3): e0149093 (Published online Mar. 9, 2016)). [cited by examiner]
Vajda et al., Current Opinion in Structural Biology, 67 pp. 226-231 (2021). [cited by examiner]
Marks et al., J. Biol. Chem. 295(29) 9823-9837 (2020). [cited by examiner]
Akbar et al., Cell Reports 34, 108856, Mar. 16, 2021). [cited by examiner]
Lo et al., BMC Genomics vol. 22, Article No. 116 (2021). [cited by examiner]
Altschul et al., “Basic Local Alignment Search Tool,” J Mol Biol 215:403-10 (1990). [cited by applicant]
Altschul et al., Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, [cited by applicant]
Altschul et al., Local alignment statistics, [cited by applicant]
Anti-CDH19 Product Datasheet, <<https://atlasantibodies.com/print_datasheet/R74953>> retrieved May 13, 2014. [cited by applicant]
Aplin et al., Preparation, properties, and applications of carbohydrate conjugates of proteins and lipids, [cited by applicant]
Arakawa et al., Protein—Solvent interactions in pharmaceutical formulations, [cited by applicant]
Artsaenko et al., Expression of a single-chain Fv antibody against abscisic acid creates a wilty phenotype in transgenic tobacco, [cited by applicant]
Bendig, Humanization of Rodent Monoclonal Antibodies by CDR Grafting, Methods: A Companion to Methods in Enzymology, 8:83-93 (1995). [cited by applicant]
Bertucci et al., Gene expression profiling of human melanoma cell lines with distinct metastatic potential identifies new progression markers. [cited by applicant]
Brühl, Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: a new strategy in the treatment of chronic inflammatory diseases and HIV, [cited by applicant]
Carter et al., High level [cited by applicant]
CDH19 monoclonal antibody (M01), clone 1G4, <<http://www.abnova.com/protocol_pdf/DS_H00028513-M01.pdf>> retrieved May 13, 2014. [cited by applicant]
Chalfie et al., Green fluorescent protein as a marker for gene expression, [cited by applicant]
Cheadle et al., Cloning and expression of the variable regions of mouse myeloma protein MOPC315 in [cited by applicant]
Chen et al., The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanoma. [cited by applicant]
Cheson et al., Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group, J. Clin. Oncol., 17(4):1244 (1999). [cited by applicant]
Chothia et al., Canonical structures for the hypervariable regions of immunoglobulins, [cited by applicant]
Chothia et al., Conformations of immunoglobulin hypervariable regions, [cited by applicant]
Chothia, et al., Structural repertoire of the human VH segments, [cited by applicant]
Clackson et al., Making antibody fragments using phage display libraries, [cited by applicant]
Cole et al., The EBV-Hybridoma technique and its application to human lung cancer, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., 77-96 (1985). [cited by applicant]
Creighton, Proteins: Structure and Molecular Properties, W. H. Freeman & Co., San Francisco, 79-86 (1983). [cited by applicant]
Cunningham et al., High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. [cited by applicant]
Dall'Acqua et al., Contribution of domain interface residues to the stability of antibody CH3 domain homodimers, [cited by applicant]
Devereux et al., A comprehensive set of sequence analysis programs for the VAX, Nucl. Acid Res., 12:387-95 (1984). [cited by applicant]
Duskin et al., Relationship of the structure and biological activity of the natural homologues of tunicamycin, [cited by applicant]
Edge et al., Deglycosylation of glycoproteins by trifluoromethanesulfonic acid, [cited by applicant]
Eppstein et al., Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor, [cited by applicant]
Fanslow et al., Structural characteristics of CD40 ligand that determine biological function, [cited by applicant]
Fecker et al., Expression of single-chain antibody fragments (scFV) specific for beet necrotic yellow vein virus coat protein or 25 kDa protein in [cited by applicant]
Feng et al., Progressive sequence alignment as a prerequisite to correct phylogenetic trees, [cited by applicant]
Gabizon et al., Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times, [cited by applicant]
Genbank Accession No. U55762, Cloning vector pEGFP-N1, complete sequence, enhanced green fluorescent protein (egfp) and neomycin phosphotransferase genes, dated Jun. 17, 1996. [cited by applicant]
George et al., Current Methods in Sequence Comparison and Analysis, Macromolecule Sequencing and Synthesis, Selected Methods and Applications, 127-49 Alan R. Liss, Inc. (1988). [cited by applicant]
Graham et al., Characteristics of a human cell line transformed by DNA from human adenovirus type 5, [cited by applicant]
Green et al., Antigen-specific human monoclonal antibodies from mice engineered with human lg heavy and light chain YACs, Nature Genetics, 7:13-21 (1994). [cited by applicant]
Green et al., Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes, [cited by applicant]
Hakimuddin et al., A chemical method for the deglycosylation of proteins, [cited by applicant]
Hawkins et al., Selection of phage antibodies by binding affinity, [cited by applicant]
Heim et al., Engineering green fluorescent protein for improved brightness, longer wavelengths and fluorescence resonance energy transfer, [cited by applicant]
Henry et al. (Frontier in Immunology 8:1-15 (Dec. 12, 2017). [cited by applicant]
Hiatt et al., Production of antibodies in transgenic plants, [cited by applicant]
Higgins et al., Fast and sensitive multiple sequence alignments on a microcomputer, [cited by applicant]
Holt et al., Domain antibodies: Proteins for therapy, Trends in Biotechnology, 21(11):484-90 (2003). [cited by applicant]
Hoppe et al., A parallel three stranded alpha-helical bundle at the nucleation site of collagen triple-helix formation, [cited by applicant]
Huston et al., Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
Hwang et al., Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study, [cited by applicant]
Ichiki et al., Regulation of the expression of human C epsilon germline transcript. Identification of a novel IL-4 responsive element, [cited by applicant]
International Preliminary Report on Patentability, PCT/EP2014/051550 (Jul. 28, 2015). [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority issued in connection with International Application No. PCT/EP2014/051550, mailed May 22, 2014. [cited by applicant]
Karlin et al., Applications and statistics for multiple high-scoring segments in molecular sequences, [cited by applicant]
Kellermann et al., Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics, [cited by applicant]
Kendrick et al., Physical stabilization of proteins in aqueous solution, [cited by applicant]
Kim et al. (Biochimica et Biophysica Acta 1844 (2014) 1983-2001). [cited by applicant]
Kipriyanov, Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics, [cited by applicant]
Kischel et al., Characterization of novel CD33-and MCSP-specific BiTE antibodies for the treatment of acute myeloid leukemia and melanoma, receptively, that are fully human in sequence. [cited by applicant]
Knappe et al., Herpesvirus saimiri-transformed macaque T cells are tolerated and do not cause lymphoma after autologous reinfusion, [cited by applicant]
Kools et al., Characterization of three novel human cadherin genes (CDH7, CDH19, and CDH20) clustered on chromosome 18q22-q23 and with high homology to chicken cadherin-7, [cited by applicant]
Kozbor, Comparison of the specific IgM and IgG antibody response in humans induced by antigen (tetanus toxoid) or a polyclonal activator (EBV) in vitro, [cited by applicant]
Kufer, Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer, [cited by applicant]
Kumar et al., Molecular cloning and expression of the Fabs of human autoantibodies in Escherichia coli. Determination of the heavy or light chain contribution to the anti-DNA/-cardiolipin activity of the Fab, J. Biol. C… [cited by applicant]
Köhler et al., Continous cultures of fused cells secreting antibody of predefined specificity, [cited by applicant]
Landschulz et al., The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins, [cited by applicant]
Langer et al., Biocompatibility of polymeric delivery systems for macromolecules, [cited by applicant]
Langer, Controlled release of macromolecules, [cited by applicant]
Lowman et al., Selecting high-affinity binding proteins by monovalent phage display, [cited by applicant]
Löffler, A recombinant bispecific single-chain antibody, CD19×CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes, [cited by applicant]
MacCallum et al., Antibody-antigen interactions: Contact analysis and binding site topography, [cited by applicant]
Mack, A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity, [cited by applicant]
Mack, Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity, [cited by applicant]
Malmborg, BIAcore as a tool in antibody engineering, [cited by applicant]
Marks et al., By-passing immunization. Human antibodies from V-gene libraries displayed on phage [cited by applicant]
Martin et al., Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting, [cited by applicant]
Martin et al., Protein Sequence and Structure Analysis of Antibody Variable Domains, [cited by applicant]
Martin et al., Structural families in loops of homologous proteins: automatic classification, modelling and application to antibodies, [cited by applicant]
Mather et al., Culture of testicular cells in hormone-supplemented serum-free medium [cited by applicant]
Mather, Establishment and characterization of two distinct mouse testicular epithelial cell lines, [cited by applicant]
Mendez et al., Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice, [cited by applicant]
Needleman et al., “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins,” J Mol Biol 48:443-53 (1970). [cited by applicant]
Niu et a., Monocyte chemotactic protein (MCP)-1 promotes angiogenesis via a novel transcription factor, MCP-1 induced protein (MCPIP). [cited by applicant]
Nolan et al., Fluorescence-activated cell analysis and sorting of viable mammalian cells based on beta-D-galactosidase activity after transduction of [cited by applicant]
Owen et al., Synthesis of a functional anti-phytochrome single-chain Fv protein in transgenic tobacco, [cited by applicant]
Paul, Fundamental Immunology, pp. 292-295, (3rd ed. 1993). [cited by applicant]
Pearson et al., Improved tools for biological sequence comparison, [cited by applicant]
Raag et al., Single-chain Fvs, [cited by applicant]
Randolph et al., Surfactant-protein interactions, [cited by applicant]
Rudikoff et al., Single amino acid substitution altering antigen-binding specificity, [cited by applicant]
Schier, Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections, [cited by applicant]
Schlereth et al., T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct, [cited by applicant]
Sidman et al., Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid, [cited by applicant]
Smith et al., Comparison of Biosequences, [cited by applicant]
Smith-Gill et al., Contributions of immunoglobulin heavy and light chains to antibody specificity for lysozyme and two haptens, J. Immunol. 139:4135-44 (1987). [cited by applicant]
Song et al., Light chain of natural antibody plays a dominant role in protein antigen binding, Biochem. Biophys. Res. Commun. 268:390-4 (2000). [cited by applicant]
Stauber, Development and applications of enhanced green fluorescent protein mutants, [cited by applicant]
Takahashi et al., Identification of a novel type II classical cadherin: rat cadherin19 is expressed in the cranial ganglia and Schwann cell precursors during development, Devl. Dynamics, 232(1):200 (2005). [cited by applicant]
Thotakura et al., Enzymatic deglycosylation of glycoproteins, [cited by applicant]
Tomlinson et al., The structural repertoire of the human V kappa domain, [cited by applicant]
Urlaub et al., Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity, [cited by applicant]
Ward et al., Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]